Summary | |
---|---|
Symbol | CD99 |
Name | CD99 molecule |
Aliases | MIC2; antigen identified by monoclonal antibodies 12E7, F21 and O13; CD99 antigen; HBA71; MIC2X; MIC2Y; MSK5 ...... |
Chromosomal Location | Xp22.32 and Yp11.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Membrane Single-pass type I membrane protein |
Domain |
PF12301 CD99 antigen like protein 2 |
Function |
Involved in T-cell adhesion processes and in spontaneous rosette formation with erythrocytes. Plays a role in a late step of leukocyte extravasation helping leukocytes to overcome the endothelial basement membrane. Acts at the same site as, but independently of, PECAM1. Involved in T-cell adhesion processes (By similarity). |
Biological Process | - |
Molecular Function | - |
Cellular Component |
GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0030055 cell-substrate junction |
KEGG |
hsa04514 Cell adhesion molecules (CAMs) hsa04670 Leukocyte transendothelial migration |
Reactome |
R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-109582: Hemostasis |
Summary | |
---|---|
Symbol | CD99 |
Name | CD99 molecule |
Aliases | MIC2; antigen identified by monoclonal antibodies 12E7, F21 and O13; CD99 antigen; HBA71; MIC2X; MIC2Y; MSK5 ...... |
Chromosomal Location | Xp22.32 and Yp11.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CD99 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between CD99 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | CD99 |
Name | CD99 molecule |
Aliases | MIC2; antigen identified by monoclonal antibodies 12E7, F21 and O13; CD99 antigen; HBA71; MIC2X; MIC2Y; MSK5 ...... |
Chromosomal Location | Xp22.32 and Yp11.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CD99 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CD99 |
Name | CD99 molecule |
Aliases | MIC2; antigen identified by monoclonal antibodies 12E7, F21 and O13; CD99 antigen; HBA71; MIC2X; MIC2Y; MSK5 ...... |
Chromosomal Location | Xp22.32 and Yp11.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CD99 in various data sets.
|
Points in the above scatter plot represent the mutation difference of CD99 in various data sets.
|
Summary | |
---|---|
Symbol | CD99 |
Name | CD99 molecule |
Aliases | MIC2; antigen identified by monoclonal antibodies 12E7, F21 and O13; CD99 antigen; HBA71; MIC2X; MIC2Y; MSK5 ...... |
Chromosomal Location | Xp22.32 and Yp11.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD99. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CD99 |
Name | CD99 molecule |
Aliases | MIC2; antigen identified by monoclonal antibodies 12E7, F21 and O13; CD99 antigen; HBA71; MIC2X; MIC2Y; MSK5 ...... |
Chromosomal Location | Xp22.32 and Yp11.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD99. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD99. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CD99 |
Name | CD99 molecule |
Aliases | MIC2; antigen identified by monoclonal antibodies 12E7, F21 and O13; CD99 antigen; HBA71; MIC2X; MIC2Y; MSK5 ...... |
Chromosomal Location | Xp22.32 and Yp11.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD99. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CD99 |
Name | CD99 molecule |
Aliases | MIC2; antigen identified by monoclonal antibodies 12E7, F21 and O13; CD99 antigen; HBA71; MIC2X; MIC2Y; MSK5 ...... |
Chromosomal Location | Xp22.32 and Yp11.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CD99 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CD99 |
Name | CD99 molecule |
Aliases | MIC2; antigen identified by monoclonal antibodies 12E7, F21 and O13; CD99 antigen; HBA71; MIC2X; MIC2Y; MSK5 ...... |
Chromosomal Location | Xp22.32 and Yp11.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CD99 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CD99 |
Name | CD99 molecule |
Aliases | MIC2; antigen identified by monoclonal antibodies 12E7, F21 and O13; CD99 antigen; HBA71; MIC2X; MIC2Y; MSK5 ...... |
Chromosomal Location | Xp22.32 and Yp11.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CD99 collected from DrugBank database. |
There is no record. |